Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Aurobindo Pharma (AUROPHARMA.NS) has a market cap of $7.73 billion USD. According to our data, Aurobindo Pharma is ranked No.1937 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $7.73 B |
-14.61%
|
| Dec 31, 2024 | $9.05 B |
23.29%
|
| Dec 29, 2023 | $7.34 B |
149.62%
|
| Dec 30, 2022 | $2.94 B |
-39.67%
|
| Dec 31, 2021 | $4.87 B |
-19.81%
|
| Dec 31, 2020 | $6.08 B |
102.95%
|
| Dec 31, 2019 | $2.99 B |
-37.39%
|
| Dec 31, 2018 | $4.78 B |
6.89%
|
| Dec 29, 2017 | $4.47 B |
3.22%
|
| Dec 30, 2016 | $4.33 B |
-23.31%
|
| Dec 31, 2015 | $5.65 B |
54.86%
|
| Dec 31, 2014 | $3.65 B |
190.43%
|
| Dec 31, 2013 | $1.26 B |
110.05%
|
| Dec 31, 2012 | $0.60 B |
124.65%
|
| Dec 30, 2011 | $0.27 B |
-67.41%
|
| Dec 31, 2010 | $0.82 B |
46.54%
|
| Dec 31, 2009 | $0.56 B |
454.08%
|
| Dec 31, 2008 | $0.10 B |
-68.64%
|
| Dec 31, 2007 | $0.32 B |
-22.78%
|
| Dec 29, 2006 | $0.42 B |
72.31%
|
| Dec 30, 2005 | $0.24 B |
25.87%
|
| Dec 31, 2004 | $0.19 B |
-23.53%
|
| Dec 31, 2003 | $0.25 B |
313.68%
|
| Dec 31, 2002 | $60.59 M |
-7.29%
|
| Dec 31, 2001 | $65.35 M |
-53.32%
|
| Dec 29, 2000 | $0.14 B |
-59.59%
|
| Dec 31, 1999 | $0.35 B |
574.62%
|
| Dec 31, 1998 | $51.35 M |
68.51%
|
| Dec 31, 1997 | $30.47 M |
62.09%
|
| Dec 31, 1996 | $18.80 M |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
 Novo Nordisk
NVO
|
$286.98 B |
70.023 B
|
Denmark
|
 Novo Nordisk A/S
NOVO-B.CO
|
$285.97 B |
64.050 B
|
Denmark
|
 Roche
ROG.SW
|
$249.63 B |
38.060 B
|
Switzerland
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Thermo Fisher Scientific
TMO
|
$166.47 B |
0.002 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 CVS Health
CVS
|
$87.00 B |
-0.003 M
|
USA
|
 Chugai Pharmaceutical
4519.T
|
$76.94 B |
0.552 B
|
Japan
|
 CSL
CSL.AX
|
$74.79 B |
-0.212 B
|
Australia
|
 GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
UK
|
| Market Cap | = | AUROPHARMA.NS Stock Price | * | AUROPHARMA.NS Shares Outstanding |
| = | $13.30 | * | 0.58 B | |
| = | $7.73 B |